TransMedics: "Organs as a Service" is Winning the Hearts of Investors

The 7investing Podcast

Контент предоставлен 7investing. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией 7investing или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.

1M ago 11:30

MP3•Главная эпизода

The "organ transplant as a service" market is taking the medical world by storm. How long can the accelerated growth rates continue?

TransMedics (Nasdaq: TMDX) is a unique company you might have never heard of. But it’s playing an important role in saving the lives of thousands of Americans every year.

As the creator of its patented Organ Care System (OCS), it is the only FDA-approved technology to transport lungs, hearts, and livers in the United States. When a registered donor is recently deceased, TransMedics’ OCS keeps their organs functional long enough to be transplanted into another patient who is badly in need. The transplant must happen as quickly and as efficiently as possible, since this is a matter of life and death.

In today's episode, 7investing CEO Simon Erickson describes this fast-growing new market and why it's eagerly being embraced by organ transplant centers. He also highlights two key risks that investors should consider when sizing up TMDX as a long-term opportunity.

461 эпизодов

#Trading #Business #7investing #Stock Market